Loading
Croda International Plc Stock: price and insider trades · United Kingdom
1 insider bought €1.5M of shares over the last 90 days, the latest filed 30 Sept 2026.
Croda International Plc: what insiders have been doing
Croda International Plc, classified in the Chemicals & Materials sector, is a listed company based in Goole, United Kingdom, founded in 1925. Its insiders report their share dealings to RNS (LSE). In the past year (18 October 2025 to 18 October 2026), 44 filings came from 17 insiders.
The record shows 8 purchases on the open market worth €2.1M, made by 5 insiders, against 7 sales worth €10.8M by 5 insiders. The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €5.6M, the sale published on 18 March 2026 by Stephen Edward Foots is the largest of the period (0.13% of market cap). Among those who bought: 2 board members, 2 senior executives and 1 finance chief.
In the case of 4 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The clock since the last published purchase (30 September 2026) now reads 17 days. Typically, a trade is published a median of 1 day after it takes place. The regulation allows three business days to notify a trade (UK MAR).
With 44 filings in twelve months, the company is more active than the median of 6 filings across the 831 companies we follow on the same exchange. Since 2023, the database holds 38 purchases and 25 sales by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Culp Inc and Gold.com, Inc. This summary is built from RNS (LSE) disclosures alone and does not predict where the share price will go.
Insider Decl.
137
Thresholds
n/a
Buy Volume
€3M
38 ops. · all time
Sell Volume
€32M
25 ops. · all time
Who traded when
BuySaleStephen Richard Oxley7 buys
Ian Alan Bull4 buys
Michelle Angela Lydon2 buys2 sales
Sandra Elaine Breene2 buys2 sales
Stephen Edward Foots1 buy3 sales
1) Thomas Michael Brophy 2) Sarah Elizabeth Brophy3 buys
+12 other insiders
Since the insiders bought
- +10.7%Entry £32.74 · Close 16 Oct 2026 £36.23
- +26.5%Entry £28.63 · Close 16 Oct 2026 £36.23
- +30.4%Entry £27.78 · Close 16 Oct 2026 £36.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Croda International Plc Buy (bullish), based on 14 analysts. Average price target: £37.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,520 of 24,161 companies
42.5
score / 100
Value39
Quality46
FCF yld3.3%
Earn yld1.2%
EV/EBITDA22.4x
ROE3.7%
Gross mgn44%
Net mgn3.6%
Debt/EBITDA2.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
£36.23
Analyst consensus
14 analystsBuy
£31.90Target £37.08(+2%)£42.50
Income statement
Revenue£1.7B
Gross profit£745.7M44% margin
EBITDA£256.2M15% margin
Net income£62M4.6% margin
Valuation
PER (trailing)64.7x
PER (forward)2042.2x
P/Book232.3x
Beta0.92
Balance sheet & cash
Market cap£5B
Total debt£696.6M
Free Cash Flow£166.6M
Debt / Equity36%
Profitability & ownership
ROE3.7%
ROA2.2%
% insiders0.7%
% institutions62.3%
Last declaration on 13 October 2026
Declarations137 total
55 shares@ £32.850.0000% mcap0.1% of flowXLONISIN GB00BJFFLV09RNS:9815703
13 shares@ £33.380.0000% mcap100.0% of flowXLONISIN GB00BJFFLV09RNS:9815791
4 shares@ £33.5150.0% of flowXLONISIN GB00BJFFLV09FCA-NSM:0493e67b-7660-49bd-9ba8-f12c92a8180b
1,692 sharesXLONISIN GB00BJFFLV09FCA-NSM:bdd63630-bdf3-4db7-b7ec-8a7be725712e
Canonical exit: 29 Dec 2026 (T+90)
325 shares@ £26.370.0002% mcap100.0% of flowN/A - Grant of an optionISIN GB00BJFFLV09RNS:9763360
4,176 shares@ £75.11310.0069% mcap22.6% of flowXLONISIN GB00BJFFLV09RNS:9710715
Canonical exit: 1 Nov 2026 (T+90)
4,176 shares@ £232.140.021% mcap69.9% of flowXLONISIN GB00BJFFLV09FCA-NSM:d2d3d375-d124-46cf-8557-16f6123078dd
Canonical exit: 1 Nov 2026 (T+90)
1,890 shares@ £33.03650.0014% mcap26.9% of flowXLONISIN GB00BJFFLV09RNS:9699016
◆
440 shares@ £108.77160.5% of flowXLONISIN GB00BJFFLV09RNS:9666054
◆
0XLONISIN GB00BJFFLV09RNS:81150c53-f71a-48c4-b1ff-3fd133b56cc3
◆
22,383 shares@ £422.3010.26% mcap30.7% of flowXLONISIN GB00BJFFLV09RNS:9614272
◆
0XLONISIN GB00BJFFLV09RNS:486d7712-882f-4315-be30-04218def9963
1,516 shares@ £74.46450.0031% mcap24.4% of flowXLONISIN GB00BJFFLV09RNS:9595377
Canonical exit: 30 Aug 2026 (T+90)
1,516 shares@ £230.16080.0095% mcap75.6% of flowXLONISIN GB00BJFFLV09RNS:11f2fbff-c828-4e07-86ca-00a1778d0225
Canonical exit: 30 Aug 2026 (T+90)
323 shares@ £182.49130.0016% mcap44.2% of flowXLONISIN GB00BJFFLV09RNS:9592636
77 shares@ £30.37750.0001% mcap0.2% of flowXLONISIN GB00BJFFLV09RNS:4ee0cce3-d66c-4c05-88c7-5ab1fbec4b0a
323 shares@ £230.16930.0020% mcap55.8% of flowXLONISIN GB00BJFFLV09RNS:a4b6ad68-0c4e-4b89-af08-d52808f1117e
5 shares@ £230.8320.0000% mcap100.0% of flowXLONISIN GB00BJFFLV09RNS:f3fcd66d-ec91-42b4-ba7c-941561df2174
5 shares@ £30.3420.0000% mcap0.0% of flowXLONISIN GB00BJFFLV09RNS:9592877
42 shares@ £30.16930.0000% mcap0.1% of flowXLONISIN GB00BJFFLV09RNS:9592637
25 of 137 declarations
About Croda International Plc
Croda International Plc is a UK-based specialty chemicals group listed on the London Stock Exchange (FTSE 100/250/AIM) in the United Kingdom. The company positions itself around “smart science”: it develops high-performance ingredients and solutions used by industrial customers and consumer brands in formulations where functionality, quality and sustainability matter. Founded in 1925, Croda marked its centenary in 2025, highlighting a long operating history and a deep technical heritage. Its global headquarters are at Cowick Hall in Yorkshire, close to its original Rawcliffe Bridge site, which remains one of the company’s UK manufacturing locations.
Croda’s business model is organised around three main divisions. Consumer Care serves markets closest to the end consumer, including beauty, personal care, home care and fragrance ingredients. Life Sciences covers pharmaceuticals, broader life sciences and agriculture, with solutions ranging from excipients and drug delivery systems to crop protection and seed enhancement technologies. Industrial Specialties addresses more technical markets such as coatings, water treatment, textiles, fibres and selected formulation-intensive industrial applications. This mix reduces reliance on any single end market while providing exposure to long-duration themes such as sustainable innovation, health, and formulation efficiency.
Read moreShow less
From a competitive perspective, Croda stands out through its scientific specialization, application-led innovation and close customer relationships. That combination helps the group build strong positions in niche segments where technical requirements are high and switching costs can be meaningful. Croda emphasizes differentiated products and collaborative development with customers, particularly in markets where speed to market, performance, and regulatory compliance are critical.
Geographically, Croda has a broad global footprint, operating across multiple countries with significant manufacturing, R&D and commercial activity in the UK, Europe, North America and Asia. The UK remains strategically important, hosting manufacturing, distribution, finance and specialist laboratory capabilities. Recent highlights include the opening in 2025 of a new lipids manufacturing facility in Pennsylvania to support its Pharma strategy, the release of 2025 full-year results showing improved momentum, and continued operational simplification and margin enhancement initiatives. The company also appointed a new CFO in 2025, underscoring an active phase of transformation at both operational and leadership levels.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations